Immunology and Breast Cancer: Toward a New Way of Understanding Breast Cancer and
Developing Novel Therapeutic Strategies Page 1 372 Clinical Advances in Hematology & …

Approximately 50% of human malignancies carry p53 mutations, which makes it a potential
antigenic target for cancer immunotherapy. Adoptive transfer with p53‐specific cytotoxic T …

Since their discovery, there has been significant progress in the understanding of dendritic
cell (DC) biology. Their capacity for priming an immune response against pathogens and …

Purpose: To conduct a phase I trial of a modified vaccinia Ankara (MVA) vaccine delivering
wild-type human p53 (p53MVA) in patients with refractory gastrointestinal cancers …

Dendritic cells (DC) are increasingly exploited for cell‐based immunotherapy. However,
limitations in ex vivo DC growth and DC functional heterogeneity have motivated …

As pre-existent immunity might be a reflection of an emerging anticancer response, the
demonstration of spontaneous T-cell responses against tumor associated antigens (TAAs) in …

Malignant cells are frequently recognized and destroyed by T cells, hence the development
of T cell vaccines against established tumors. The challenge is to induce protective type 1 …

Dendritic cells (DCs) are the most potent professional antigen-presenting cells, capable of
initiating proper adaptive immune responses. Although tumor-infiltrating DCs are able to …

Peptide-based cancer vaccines have been shown to boost immune systems to kill tumor
cells in cancer patients. However, designing an effective T cell epitope peptide-based …

Our laboratory has developed a process for generating mAbs with selectivity to unique
peptides in the context of MHC molecules. Recently, we reported that RL4B, an mAb that we …